News

The month in review spotlights renal regulatory news and clinical trial data as well as coverage of the 62nd European Renal Association Congress.

A relatively quiet quarter for hematology, punctuated by both successes and failures in clinical trials and a handful of Orphan Drug and Fast Track designations.

This month in review captures 5 allergy news in June, from FDA approvals to phase 3 data.

The month in review spotlights hepatic regulatory news, new clinical trial data, and novel research about liver disease risk factors.

Our Q2 2025 recap for ophthalmology highlights 5 regulatory updates, 5 important trial announcements, and top perspectives in eyecare.

June 2025 saw more research emerge in asthma therapeutics and management as well as rarer pulmonary diseases.

This FDA news recap highlights some of the most notable approvals and actions by the organization in dermatology during Q2 2025.

The month in review spotlights perspectives on collaborative GI care, updates in C diff, and new research about disorders of gut brain interaction.

The FDA distributed several designations and many trials successfully met their endpoints during an eventful June for hematology.

In our recap for Q2 in dermatology, we spotlight clinical trial findings, recent updates, and advancements in different disease states.

Chang explains the importance of collaboration between gastroenterologists and allergists in EoE care and praises recent ACG guidelines on disease management.

This Month in Review summary includes a list of some of the most impactful news in the dermatology space from June 2025.

June was characterized by HCPLive’s coverage of the AOA 2025 Conference in Minneapolis and a host of cross-specialty disease indicators and drug uses.

The CRL cited deficiencies previously identified at a third-party manufacturing vendor unrelated to OLC, and the Company plans to request a Type A meeting.

In the BE BRIGHT trial presented at SDPA 2025, patients receiving continuous bimekizumab therapy maintained high PASI 90 and PASI 100 response rates over 5 years.

This 4-year data highlights dupilumab’s efficacy among children under the age of 12 with atopic dermatitis.

At SDPA 2025, Theodore Rosen, MD, discussed various psychological disorders, including delusions of parasitosis, excoriation disorder, dermatitis artefacta, and others.

Maria Hordinsky, MD, spoke at SDPA regarding her talk highlighting a variety of clinical pearls for spotting scarring alopecia early.

At SDPA 2025, Gordon presented on the future of dermatology, discussing current drugs being evaluated for atopic dermatitis, psoriasis, and hidradenitis suppurativa.

In her SDPA interview, Maria Hordinsky, MD, spoke about her session regarding clinical pearls for clinicians seeking to spot alopecia early in patients.

At SDPA 2025, Spizuoco discussed how trichoscopic signs like black dots, yellow dots, and exclamation hairs guide treatment decisions.

This interview segment with Scherer highlights additional takeaways from his SDPA 2025 talk, covering clues for clinicians to identify different interdigital foot infections.

In this interview at SDPA, Scherer provides an overview of foot web space infections, fungal versus bacterial infections, and more.

At SDPA 2025, Cotter highlights clinical patterns in alopecia areata that may respond better, or worse, to JAK inhibition and shares his approach to systemic therapy.

Attar discusses the medication pipeline, possible AI implementation, and the importance of making patients aware of clinical trials for rare genetic diseases.

This presentation, covered at SDPA, features a discussion by Ginette Okoye, MD, who highlights diagnostic challenges among even experienced clinicians.

Lang discusses his expectations and excitement for upcoming developments in the field and encourages clinicians to work together to better treat complex patients.